Patients with malignant mesothelioma and their families are not the only ones impacted by the costs associated with the asbestos-linked cancer. There is also a societal economic burden that can run into the hundreds of millions of dollars. That is the conclusion of a new report published by Canadian occupational medicine and public health experts in the journal Occupational and Environmental Medicine. A History of … Continue reading The Economic Burden of Malignant Mesothelioma
New research out of Canada suggests that mesothelioma tumor thickness could be used to help predict mesothelioma survival and select the best treatments. Doctors at the University of Toronto compared the thickness of pleural mesothelioma tumors in 65 patients who had not yet received any treatment with their eventual outcomes and found a definite correlation. Summarizing their research in The European Respiratory Journal, the team … Continue reading Mesothelioma Tumor Thickness May Help Predict Treatment Outcomes
There is more evidence this week that the tumor suppressor gene known as BRCA1-associated protein 1 (BAP1) could help doctors distinguish pleural mesothelioma from other types of lung cancer – even cancers that commonly spread to the pleura. Pleural mesothelioma is unique among cancers in that it starts on the pleural membrane that surrounds the lungs. When other types of cancers metastasize to this region, … Continue reading Gene Test May Help Distinguish Pleural Mesothelioma from Lung Cancer
A team of international researchers say they have identified a promising new biomarker for malignant pleural mesothelioma, a rare but deadly cancer caused by exposure to asbestos. A biomarker is a compound found in the tissue, blood or other body fluid that is produced in higher amounts when disease is present. In the case of a new report presented at the annual International Association for … Continue reading International Team Identifies Potential New Mesothelioma Biomarker
Canadian researchers say the mesothelioma drug pemetrexed (Alimta) might make a good option for the specialized treatment known as heated intraperitoneal chemotherapy (HIPEC), as long as the temperature is just right. Approved by the FDA in 2004, pemetrexed is still the only drug specifically approved for the treatment of malignant mesothelioma. Mesothelioma patients typically receive it systemically, through infusion, along with a platinum-based drug like … Continue reading A New Option for HIPEC Mesothelioma Treatment?
Pathologists in Canada and France have identified what they believe are two of the most important tests for distinguishing between a benign growth on the mesothelial membrane and malignant mesothelioma. Their work could be a key step toward better, more accurate mesothelioma diagnosis. The Challenge of Mesothelioma Diagnosis Associated almost exclusively with asbestos exposure, malignant mesothelioma is one of the most aggressive and lethal types … Continue reading New Tests May Lead to Earlier, More Accurate Mesothelioma Diagnosis
There is some good news this week for peritoneal mesothelioma patients considering cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Not only can the procedure provide long-term mesothelioma survival, but even patients who have complications experience an improved quality of life within six months. The news is based on two newly-published studies, one conducted in France and the other in Canada. CRS/HIPEC for Long-Term Mesothelioma … Continue reading Specialized Mesothelioma Procedure Provides Long Survival, Good Life Quality
Targeted radiotherapy may be just as safe a way to prepare people for radical mesothelioma surgery as chemotherapy and may even result in less need for blood transfusion. That is the conclusion of a team of Canadian researchers who ran the first ever comparison of induction chemotherapy and induction radiotherapy in mesothelioma surgical outcomes. Induction Therapy for Mesothelioma In the context of mesothelioma treatment, induction … Continue reading Therapy Before Mesothelioma Surgery: Which is Better?
The medical community remains deeply divided over the risks and benefits of surgery for malignant pleural mesothelioma, making the decision even more difficult for mesothelioma patients and their families. But researchers in Canada and Japan believe they have come up with a better way to make the decision process easier. The team has devised a scoring system based on a blood test to predict which … Continue reading Blood Test Predicts Mesothelioma Surgery Outcomes
Mesothelioma experts around the world are expressing excitement about the potential of the recently FDA-approved cancer drug Keytruda (pembrolizumab). The latest doctors to join the discussion on this possible mesothelioma treatment are medical oncologists from Princess Margaret Cancer Center in Toronto. Dr. Safiya Karim and Dr. Natasha Leighl examine the “current landscape and future directions” for Keytruda as a treatment for mesothelioma in an article in … Continue reading Mesothelioma Community Hopeful About Newly Approved Immunotherapy Drug